Pharma and Life Sciences

PwC in the 'Pharma and Life Sciences' sector

Looking into the future

Thanks to our pharmaceutical and life science research, your company's future prospects look good.

Pharma 2020

Our experience in your business sector

We know your industry – therefore you can depend on our expertise and rely on our global track record.

Case study: Lonza

Strategic support

Our global network partner "Strategy &" will show you how to successfully carry out corporate transformations - with only minimal side effects.

Learn more

Learn more about the future today

Decision makers in pharmaceutical and life science companies face major challenges every day: rising energy costs, pressure to innovate, large-scale investment, global competition and tougher environmental and climate-protection regulations. We can help you to overcome them.

Our expertise

Compliance

The company's reputation and respect for regulations are key themes. We can help you find answers.

View more

Research and development

Encouraging innovation without increasing your business risk is a major challenge. We can provide you with the right tools to cope with this task.

View more

Value creation

Are your company's costs and revenues properly aligned? We can show you ways to optimise - from purchasing to sales.

View more

Intellectual property

Customised strategies are required to withstand competition from generic and counterfeit products,. We can help you to find the right measures.

View more

Global growth

New partnerships open up access to new markets. If you understand these new environments, you can look for success beyond your national boundaries.

View more

Data analysis

Companies generate vast quantities of data every day. Can you link the relevant information and thus make the right decisions? Our data analysts can provide you with a solid foundation.

View more

Research and insights

Life Science Roundtable - The Impact of the European VAT regime

Life Science Roundtable - The Impact of the European VAT regime

The indirect tax climate in the EU is drastically changing. The VAT gap of 150 billion forced the Member States to act rapidly thus resulting in a quick fix agreement and modernization of their approach increasingly using technologies. These quick fixes aim at strengthening the system till the implementation of the definitive VAT regime. One of the most impacting changes for Swiss based companies would be the introduction of the new type of taxable person. The CTP (“certified taxable person”) would be eligible to apply VAT simplifications and reverse charge, i.e. allowing cash flow advantageous VAT treatment. So far the eligibility to such certification is limited to EU based companies similarly to the Agreed Economic Operator status. During our roundtable, we will discuss how these changes might impact the Pharma life science Swiss-based entities and the actions to be taken.
Analyse de la capacité de protection des hôpitaux dans le domaine informatique : Votre organisation est-elle prête à faire face à un cyberincident?

Analyse de la capacité de protection des hôpitaux dans le domaine informatique : Votre organisation est-elle prête à faire face à un cyberincident?

La question n'est plus de savoir si un hôpital va subir une cyberattaque, mais plutôt quand. À l'heure actuelle, la sécurité informatique ne comporte pas uniquement des mesures de protection, mais également des possibilités de détection et de réaction face aux cyberattaques. Les technologies, les processus et les ressources humaines appropriés sont donc nécessaires.
Load more

Our expert

Dominik Hotz

Partner Advisory, Basel

+41 58 792 53 09

Email

Events Publications Press room Career About PwC

© 2017 - 2018 PwC. PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.